Janssen reports positive renal outcomes in new Invokana trial

Janssen has announced the findings of a new clinical study that demonstrate the positive renal outcomes associated with its type 2 diabetes therapy Invokana.

Analyses from the landmark CANVAS clinical trial programme have shown that Invokana led to improved renal outcomes and potential renal protective effects in patients with type 2 diabetes who had or were at risk for cardiovascular disease.

Compared to placebo, the canagliflozin therapy helped to reduce the risk of kidney disease progression – including significantly reducing urinary albumin excretion and stabilising estimated glomerular filtration rate – over more than six years.

Vlado Perkovic, professor of medicine at the University of New South Wales in Sydney, said: "New data from the CANVAS programme clearly indicate better renal outcomes for people treated with canagliflozin, and suggest that this agent protects kidney function, in addition to providing previously presented cardiovascular benefits."

CANVAS is the longest, largest and broadest completed cardiovascular outcomes programme of any sodium glucose cotransporter 2 inhibitor therapy to date, with more than 10,000 patients involved in the trial.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.